Rectal Benign Neoplasm disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: RCT036 MIFTS: 52	Rectal Benign Neoplasm Categories: Cancer diseases, Gastrointestinal diseases	Data Licensing For inquiries, contact: [email protected]
Genes Variations Tissues Related diseases Publications Drugs Expand all tables

Sources

Aliases & Classifications for Rectal Benign Neoplasm

MalaCards integrated aliases for Rectal Benign Neoplasm:

Name: Rectal Benign Neoplasm ¹¹ ¹⁴

Primary Malignant Neoplasm of Rectum ³³

Neoplasm of the Rectum ⁵

Primary Rectal Cancer ³³

Rectal Ampulla Cancer ³³

Cancer of the Rectum ³³

Carcinoma of Rectum ³³

Neoplasm of Rectum ¹¹

Rectal Carcinoma ³³

Rectal Neoplasms ⁴³

Rectum Neoplasm ¹¹

Rectal Cancer ³³

Rectal Tumor ¹¹

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Gastrointestinal diseases

See all MalaCards categories (disease lists)

ICD11: ³³

Neoplasms

Malignant neoplasms, except primary neoplasms of lymphoid, haematopoietic, central nervous system or related tissues

Malignant neoplasms, stated or presumed to be primary, of specified sites, except of lymphoid, haematopoietic, central nervous system or related tissues

Malignant neoplasms of digestive organs

Malignant neoplasms of intestine

Malignant neoplasms of large intestine

Malignant neoplasms of rectum

Malignant neoplasms of rectum, unspecified

Other specified malignant neoplasms of rectum

External Ids:

Disease Ontology ¹¹ DOID:1984

MeSH ⁴³ D012004

NCIt ⁴⁹ C3350

SNOMED-CT ⁶⁸ 126847008

ICD11 ³³ 1113099195 1113099195/other 1113099195/unspecified

UMLS ⁷¹ C0034885

Sources

Summaries for Rectal Benign Neoplasm

MalaCards based summary: Rectal Benign Neoplasm, also known as primary malignant neoplasm of rectum, is related to rectosigmoid junction neoplasm and familial colorectal cancer. An important gene associated with Rectal Benign Neoplasm is MSH2 (MutS Homolog 2), and among its related pathways/superpathways are TCR Signaling (Qiagen) and Endometrial cancer. The drugs Tramadol and Ketorolac have been mentioned in the context of this disorder. Affiliated tissues include lymph node, colon and liver, and related phenotype is neoplasm.

Sources

Related Diseases for Rectal Benign Neoplasm

Diseases related to Rectal Benign Neoplasm via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1072)

#	Related Disease	Score	Top Affiliating Genes
1	rectosigmoid junction neoplasm	32.2	MLH1 KRAS CEACAM5
2	familial colorectal cancer	32.0	TP53 MSH2 MLH1
3	appendix adenocarcinoma	31.0	TP53 MSH6 KRAS HRAS CEACAM5
4	anus cancer	30.8	TP53 KRAS HRAS CEACAM5 CAGE1
5	familial adenomatous polyposis	30.8	TP53 MSH6 MSH2 MLH1 KRAS HRAS
6	mucinous adenocarcinoma	30.7	TP53 MSH6 MSH2 MLH1 KRAS HRAS
7	peripheral nervous system disease	30.7	TP53 MIR31 MIR17 MIR145 MIR143 KRAS
8	lynch syndrome 1	30.7	MSH6 MSH2 MLH1
9	rectosigmoid cancer	30.7	MSH6 MSH2 MLH1 KRAS HRAS CEACAM5
10	mismatch repair cancer syndrome 1	30.7	MSH6 MSH2 MLH1
11	lung benign neoplasm	30.5	TP53 KRAS HRAS
12	diffuse gastric cancer	30.5	TP53 MSH6 MSH2 MLH1 KRAS
13	rectum cancer	30.4	TP53 RAB11B MSH6 MSH2 MLH1 MIRLET7A1
14	lynch syndrome	30.3	TP53 MSH6 MSH2 MLH1 MIR31 MIR17
15	adenosquamous carcinoma	30.3	KRAS HRAS CEACAM5
16	anus disease	30.3	TP53 KRAS HRAS CEACAM5 CAGE1
17	pseudomyxoma peritonei	30.3	TP53 KRAS CEACAM5
18	cholangitis, primary sclerosing	30.3	TP53 KRAS HRAS CEACAM5
19	vulva cancer	30.2	TP53 HRAS CEACAM5
20	gastrointestinal system disease	30.2	MIRLET7A1 MIR99A MIR31 MIR20A MIR17 MIR145
21	transverse colon cancer	30.2	MLH1 KRAS HRAS CEACAM5
22	signet ring cell adenocarcinoma	30.2	TP53 MSH6 MSH2 MLH1 KRAS HRAS
23	cervical cancer	30.2	TP53 MIR31 MIR20A MIR17 MIR143 HRAS
24	intrahepatic cholangiocarcinoma	30.2	TP53 MIR17 KRAS HRAS CEACAM5
25	myoma	30.2	TP53 KRAS CEACAM5
26	desmoid tumor	30.2	TP53 MSH6 MSH2
27	nasopharyngeal carcinoma	30.2	TP53 MIR99A MIR31 MIR17 MIR145 MIR143
28	body mass index quantitative trait locus 11	30.1	TP53 MIRLET7A1 MIR99A MIR20A MIR17 MIR143
29	endometriosis	30.1	TP53 MIR99A MIR20A MIR17 MIR145 MIR143
30	carcinosarcoma	30.1	TP53 KRAS HRAS
31	myeloma, multiple	30.1	TP53 MIR17 MIR145 KRAS HRAS
32	lung large cell carcinoma	30.0	TP53 KRAS HRAS
33	inherited cancer-predisposing syndrome	30.0	TP53 MSH6 MSH2 MLH1
34	bap1 tumor predisposition syndrome	30.0	TP53 MSH6 MSH2 MLH1
35	adenocarcinoma in situ	30.0	TP53 KRAS HRAS CEACAM5
36	mismatch repair cancer syndrome	30.0	TP53 MSH6 MSH2 MLH1 KRAS HRAS
37	suppression of tumorigenicity 12	29.9	TP53 MIR145 HRAS
38	diffuse large b-cell lymphoma	29.9	MIR99A MIR17 MIR145 MIR143
39	breast adenocarcinoma	29.9	TP53 KRAS HRAS CEACAM5
40	microinvasive gastric cancer	29.9	TP53 MLH1 MIR20A CEACAM5
41	adenoma	29.9	TP53 MSH6 MSH2 MLH1 KRAS HRAS
42	cervical squamous cell carcinoma	29.9	TP53 MLH1 KRAS CEACAM5
43	larynx cancer	29.9	TP53 MIR31 MIR17 MIR145 MIR143
44	lymphoma, non-hodgkin, familial	29.9	TP53 MSH2 MIR31 MIR20A MIR17 MIR145
45	arteries, anomalies of	29.9	MIRLET7A1 MIR20A MIR17 MIR145 MIR143
46	gastrointestinal stromal tumor	29.9	TP53 KRAS HRAS CEACAM5
47	bladder cancer	29.8	TP53 MSH2 MLH1 MIR99A MIR31 MIR17
48	adenocarcinoma	29.8	TP53 MSH6 MSH2 MLH1 KRAS HRAS
49	kidney cancer	29.8	TP53 MIR20A MIR17 MIR145
50	rectal disease	29.8	TP53 KRAS HRAS CEACAM5 CAGE1

Graphical network of the top 20 diseases related to Rectal Benign Neoplasm:

Sources

Symptoms & Phenotypes for Rectal Benign Neoplasm

MGI Mouse Phenotypes related to Rectal Benign Neoplasm:

⁴⁵

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	neoplasm	MP:0002006	9.23	CEACAM5 HRAS KRAS MIR31 MLH1 MSH2

Sources

Drugs & Therapeutics for Rectal Benign Neoplasm

Drugs for Rectal Benign Neoplasm (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 460)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Tramadol

Approved, Investigational

Phase 4

27203-92-5

33741 5523

Ketorolac

Approved

Phase 4

74103-06-3, 66635-83-4

3826

Ketamine

Approved, Vet_approved

Phase 4

6740-88-1, 1867-66-9

3821

Methadone

Approved

Phase 4

76-99-3, 1095-90-5

4095

Gabapentin

Approved, Investigational

Phase 4

60142-96-3

3446

Hydromorphone

Approved, Illicit

Phase 4

466-99-9, 71-68-1

5284570

Hydrocodone

Approved, Illicit, Investigational

Phase 4

125-29-1

5284569

Orphenadrine

Approved

Phase 4

83-98-7

4601

Morphine

Approved, Investigational

Phase 4

57-27-2

5288826

Iron

Approved

Phase 4

7439-89-6

29936

Ertapenem

Approved, Investigational

Phase 4

153832-46-3

150610

Sodium citrate

Approved, Investigational

Phase 4

68-04-2

23431961

Sildenafil

Approved, Investigational

Phase 4

139755-83-2, 171599-83-0

5212 135398744

Udenafil

Approved, Investigational

Phase 4

268203-93-6

6918523 135413547

Dexmedetomidine

Approved, Experimental, Vet_approved

Phase 4

86347-14-0, 113775-47-6

68602 5311068

Fentanyl

Approved, Illicit, Investigational, Vet_approved

Phase 4

437-38-7

3345

Droperidol

Approved, Vet_approved

Phase 4

548-73-2

3168

Sevoflurane

Approved, Vet_approved

Phase 4

28523-86-6

5206

Propofol

Approved, Investigational, Vet_approved

Phase 4

2078-54-8

4943

Bupivacaine

Approved, Investigational

Phase 4

2180-92-9, 38396-39-3

2474

Framycetin

Approved, Experimental, Vet_approved

Phase 4

1404-04-2, 119-04-0, 3947-65-7

413349 8378

Citric acid

Approved, Nutraceutical, Vet_approved

Phase 4

77-92-9

311

Anticonvulsants

Phase 4

Cytochrome P-450 Enzyme Inhibitors

Phase 4

Parasympatholytics

Phase 4

Acetaminophen, hydrocodone drug combination

Phase 4

Ketorolac Tromethamine

Phase 4

Antiparkinson Agents

Phase 4

Excitatory Amino Acid Antagonists

Phase 4

Anesthetics, Dissociative

Phase 4

Antitussive Agents

Phase 4

Muscarinic Antagonists

Phase 4

Cholinergic Antagonists

Phase 4

Ferric Oxide, Saccharated

Phase 4

Iron Supplement

Phase 4

Narcotics

Phase 4

Phosphodiesterase 5 Inhibitors

Phase 4

Citrate

Phase 4

Adrenergic alpha-Agonists

Phase 4

Adrenergic Agonists

Phase 4

Anesthetics

Phase 4

Anesthetics, Intravenous

Phase 4

Anesthetics, Inhalation

Phase 4

Anesthetics, General

Phase 4

Anesthetics, Local

Phase 4

Antibiotics, Antitubercular

Phase 4

Cobalt

Approved, Experimental, Withdrawn

Phase 3

7440-48-4

104729

Etodolac

Approved, Investigational, Vet_approved

Phase 3

41340-25-4

3308

Propranolol

Approved, Investigational

Phase 3

318-98-9, 525-66-6

62882 4946

Lanreotide

Approved

Phase 3

108736-35-2

71349 6918011

Interventional clinical trials:

(show top 50) (show all 1533)

#	Name	Status	NCT ID	Phase	Drugs
1	Multimodal Narcotic Limited Perioperative Pain Control With Colorectal Surgery as Part of an Enhanced Recovery After Surgery Protocol: A Randomized Prospective Single- Center Trial.	Unknown status	NCT02958566	Phase 4	Acetaminophen;Gabapentin;Orphenadrine;Lidocaine;Marcaine;Ketamine;Methadone;Tramadol;Ketorolac;Morphine Sulfate;Fentanyl;Dilaudid;Hydrocodone-Acetaminophen Tab 5-325 MG;HYDROCODONE/ACETAMINOPHEN 5 Mg-325 Mg ORAL TABLET
2	Randomized, Parallel Group, Clinical Trial Comparing Intravenous Iron Sucrose Versus Oral Ferrous Sulphate in the Treatment of Perioperative Iron Deficiency in Patients With Colo-Rectal Neoplasm and Iron Deficiency Anemia.	Unknown status	NCT00199277	Phase 4	i.v. iron sucrose;Oral iron
3	Konzentrationen Von Ertapenem in Kolorektalem Gewebe	Completed	NCT00535652	Phase 4	Ertapenem
4	Compression Anastomosis: Initial Clinical Experience With the ColonRingTM	Completed	NCT01056913	Phase 4
5	A Non-randomised Controlled Trial of Early Intervention to Preserve Erectile Function After Laparoscopic Resection for Rectal Cancer	Completed	NCT01912586	Phase 4
6	The Efficacy of Penile Rehabilitation Using Udenafil After Total Mesorectal Excision of Rectal Cancer	Completed	NCT01421940	Phase 4	Placebo drug;Udenafil
7	Prospective Randomized Study of Single Incision Laparoscopic Surgery Versus Conventional Laparoscopic Surgery for Rectal Cancer	Completed	NCT01579721	Phase 4
8	Assessment of the Effect of Dexmedetomidine in the Management of Postoperative Pain When Combined With Fentanyl in the Patient-controlled Analgesia	Completed	NCT01373021	Phase 4	Fentanyl;Dexmedetomidine
9	Low-dose Neuroleptanalgesia Reduce the Occurrences of Postoperative Delirium in Elderly Patients Undergoing Non-cardiac Major Surgery : a Randomized Controlled Trial	Recruiting	NCT05068180	Phase 4	low-dose neuroleptanalgesia;Placebo
10	A Randomized, Open-label Study to Compare Propofol Anesthesia With Sevoflurane Anesthesia in Terms of Overall Survival in Patients With Surgical Intervention for Either Breast-, Colon- or Rectal Cancer	Recruiting	NCT01975064	Phase 4	Propofol;Sevoflurane
11	Total Neoadjuvant Therapy in Rectal Cancer Treatment	Recruiting	NCT04747951	Phase 4	consolidation chemotherapy;adjuvant chemotherapy
12	Neoadjuvant Chemoradiation With Irinotecan Guided by UGT1A1 Status in Patients With Locally Advanced Rectal Cancer: A Real-Word Multi-center Study	Recruiting	NCT05148767	Phase 4	Neoadjuvant chemoradiotherapy based on irinotecan
13	Spinal Analgesia for Laparoscopic Abdominoperineal Rectal Amputation Using an Enhanced Recovery After Surgery Program: a Randomized Double-blind Placebo-controlled Trial	Recruiting	NCT05406765	Phase 4	Bupivacaine Injection
14	Mechanical Bowel Preparation and Oral Antibiotics Versus Mechanical Bowel Preparation Only Prior Rectal Surgery - a Prospective, Randomized Controlled Trial	Active, not recruiting	NCT04281667	Phase 4	Oral Antibiotics;Placebo;Mechanical Bowel Preparation
15	Transanal Endoscopic Microsurgery Versus Endoscopic Submucosal Dissection For Large Rectal Adenomas	Suspended	NCT01023984	Phase 4
16	Evaluating the Radial Reload Stapler With Tri-Staple TM Technology During Laparoscopic Low Anterior Resection for Rectal Cancer: A Prospective Multicenter Case Series	Terminated	NCT01706822	Phase 4
17	Preoperative Chemoradiation Versus Short Term Radiation Alone With Delayed Surgery for Stage II and III Resectable Rectal Cancer	Unknown status	NCT00597311	Phase 3
18	5FU/VL Vs LV5FU2 + CPT11 in Stage II-III Resected Rectal Cancer	Unknown status	NCT00189657	Phase 3
19	RANDOMIZED TRIAL OF CONCOMITANT PREOPERATIVE RADIO-CHEMOTHERAPY WITH OR WITHOUT POSTOPERATIVE CHEMOTHERAPY IN LOCALLY ADVANCED RECTAL CARCINOMA	Unknown status	NCT00002896	Phase 3	chemotherapy;fluorouracil;leucovorin calcium
20	Anastomotic Leakage in Laparoscopic Anterior Resection With or Without "Dog Ear" Double-stapled Anastomosis for Rectal Cancer : A Prospective, Randomized, Controlled Study	Unknown status	NCT02770911	Phase 3
21	Resource-Sparing Curative Treatment for Rectal Cancer	Unknown status	NCT01459328	Phase 3
22	The Role of Indocyanine Green (ICG) Fluorescence Imaging on Anastomotic Leak and Short-term Outcomes in Robotic Colorectal Surgery: A Prospective Randomized Trial	Unknown status	NCT02598414	Phase 2, Phase 3
23	Nano MRI on 7 Tesla: a Technical Validation Study in Rectal and Breast Cancer	Unknown status	NCT02751606	Phase 3	ferumoxtran-10
24	Randomized Controlled Trial to Evaluate High Tie Versus Low Tie of the Inferior Mesenteric Artery in Rectal Anterior Resection for Rectal Cancer Patients	Unknown status	NCT01861678	Phase 3
25	Investigation of the Value of ctDNA Analysis in the Diagnosis, Treatment, and Surveillance of Patients With Surgically Resectable Colorectal Cancer	Unknown status	NCT03038217	Phase 3	Capecitabine +/- Oxaliplatin
26	A Comparison for Laparoscopically Assisted and Open Surgery for Advanced Rectal Cancer After Preoperative Chemoradiation- Randomized Prospective Trial	Unknown status	NCT00470951	Phase 3
27	Short-course Preoperative Radiotherapy With Consolidating Chemotherapy vs. Preoperative Chemoradiation in Patients With Unresectable Rectal Cancer: Phase III Study	Unknown status	NCT00833131	Phase 3
28	The Randomised Study of Preoperative Radiotherapy and Local Excision for Radiosensitive Rectal Cancer	Unknown status	NCT00738790	Phase 3
29	A Randomized Phase III Trial of Capecitabine With or Without Irinotecan Driven by UGT1A1 in Neoadjuvant Chemoradiation of Locally Advanced Rectal Cancer	Unknown status	NCT02605265	Phase 3	Capecitabine;Irinotecan;Oxaliplatin
30	A Randomized Trial Comparing Concurrent Chemoradiation Versus Wide Pelvic Lymphadenectomy for Advanced Rectal Cancer	Unknown status	NCT00154752	Phase 3
31	INTEnsification Radiotherapy With Accelerated Fractionation or ChemoTherapy And Local Excision After 3D External Radio-chemotherapy	Unknown status	NCT01653301	Phase 3	XELAC RT;XELOX RT
32	Randomized Controlled Trial Comparing the Bladder and Sexual Functions of Patients Who Undergo Laparoscopic and Robotic Assisted Resection for Rectal Cancer	Unknown status	NCT01130233	Phase 3
33	A Randomized Controlled Clinical Trial Comparing Oncological Results and Functional Recovery Between Laparoscopic and Open Method for the Treatment of Advanced Rectal Cancer After Concurrent Chemoradiation Therapy (CCRT)	Unknown status	NCT00601549	Phase 3
34	Randomized Trial of Wide Mesorectal Excision Versus Total Mesorectal Excision for Mid Rectal Cancer	Unknown status	NCT00007930	Phase 3
35	A Randomized Clinical Trial Comparing Laparoscopic and Open Surgery for Rectal Cancer.	Unknown status	NCT00297791	Phase 3
36	(MansTaTME) Trans-anal Versus Laparoscopic Total Mesorectal Excision for Mid and Low Rectal Cancer	Unknown status	NCT03242187	Phase 2, Phase 3
37	A Clinical Trial Comparing Preoperative Radiation Therapy And Capecitabine With or Without Oxaliplatin With Preoperative Radiation Therapy And Continuous Intravenous Infusion Of 5-Fluorouracil With or Without Oxaliplatin In The Treatment Of Patients With Operable Carcinoma Of The Rectum	Unknown status	NCT00058474	Phase 3	capecitabine;fluorouracil;oxaliplatin
38	An Open Label, Randomized, Multi-center, Phase II/III Trial of High Intensity Versus Low Intensity Neoadjuvant Chemoradiotherapy With Intensity-modified Radiation Therapy (IMRT) in Local Advanced Rectal Cancer	Unknown status	NCT01064999	Phase 2, Phase 3	Oxaliplatin;Capecitabine
39	A Phase III, Randomized, Double-Blind Placebo Controlled Study of the Probiotic Preparation VSL#3® Versus Placebo in Increasing the Pathological Major Response Rate in Patients Receiving Concurrent Chemotherapy and Pelvic Radiation Therapy	Unknown status	NCT01579591	Phase 3
40	Efficacy and Safety of LifeSeal™ Kit for Staple Line Sealing in Colorectal and Coloanal Anastomoses: A Prospective Randomized Study	Unknown status	NCT02907385	Phase 3
41	A Trial to Assess Robot-assisted Surgery and Laparoscopy-assisted Surgery in Patients With Mid or Low Rectal Cancer	Unknown status	NCT01423214	Phase 3
42	A Phase II/III Randomized Controlled Study of Neoadjuvant FOLFOX6 Treatment With or Without Radiation Compared to 5-Fu Based Chemoradiation in Treating Patients With Resectable Rectal Cancer	Unknown status	NCT01211210	Phase 2, Phase 3	fluorouracil;fluorouracil, oxaliplatin
43	The Safety and Effect of Transanual Tube Placement in Low Anterior Resection (LAR) for Rectal Cancer to Prevent Anastomotic Leak: Randomized Control Trial Study	Unknown status	NCT02905968	Phase 2, Phase 3
44	Preoperative Hyperfractionated Radiotherapy Versus Combined Radiochemotherapy for Patients With Locally Advanced Rectal Cancer: a Phase III Randomized Trial.	Unknown status	NCT01814969	Phase 3
45	A Phase III Randomised Study Of J-Pouch Coloanal Anastomosis Versus Side-To-End Coloanal Anastomosis After Preoperative Radiotherapy And Total Mesorectal Excision In Patients With Mid And Distal Rectal Cancer	Unknown status	NCT00070005	Phase 3
46	Two-Week COurse Versus Conventionally Fractionated Preoperative Chemoradiotherapy In Locally Advanced Rectal Cancer (TwoArc Trial): A Phase III Randomized Clinical Trial	Unknown status	NCT02484040	Phase 3	Two-week course of radiation
47	Perioperative β-adrenergic Blocker and a COX2 Inhibitor in Patients Undergoing Resection for Primary Colon and Rectal Cancer: Effect on Tumor Recurrence and Postoperative Immune Perturbations. A Multicenter Randomized Prospective Trial.	Unknown status	NCT00888797	Phase 3	Propranolol and Etodolac
48	A Phase III, Randomized Study of Adjuvant Chemotherapy for Patients With Rectal Adenocarcinoma Who Achieved Suboptimal Response After Neoadjuvant Chemo-radiotherapy.	Unknown status	NCT01941979	Phase 3	5-FU, Capecitabine, Oxaliplatin, Leucovorin.
49	A Phase III Multi-Center Randomized Clinical Trial to Evaluate the Safety and Efficacy of CoFactor and 5-Fluorouracil (5-FU) Plus Bevacizumab Versus Leucovorin and 5-FU Plus Bevacizumab as Initial Treatment for Metastatic Colorectal Carcinoma	Unknown status	NCT00337389	Phase 3	5- Fluorouracil (5-FU);bevacizumab (Avastin);Leucovorin;CoFactor (ANX-510)
50	A Phase III Study Evaluating Two Neoadjuvant Treatments Radiochemotherapy (5 Weeks - 50Gy+Capecitabine) and Radiotherapy (1week - 25Gy) in Patient Over 75 With Locally Advanced Rectal Carcinoma	Completed	NCT02551237	Phase 3	Capecitabine

Search NIH Clinical Center for Rectal Benign Neoplasm

Cochrane evidence based reviews: rectal neoplasms

Sources

Genetic Tests for Rectal Benign Neoplasm

Sources

Anatomical Context for Rectal Benign Neoplasm

Organs/tissues related to Rectal Benign Neoplasm:

MalaCards : Lymph Node, Colon, Liver, T Cells, Prostate, Lung, Bone Marrow

Sources

Publications for Rectal Benign Neoplasm

Articles related to Rectal Benign Neoplasm:

(show top 50) (show all 31298)

#	Title	Authors	PMID	Year
1	Incidental findings on staging CT for rectal cancer: Frequency, clinical significance and outcomes. ⁶²	Tang YZ...Alabousi A	36356382	2023
2	Impact of endorectal filling on interobserver variability of MRI based rectal primary tumor delineation. ⁶²	Lo Russo M...Gani C	36299279	2023
3	BioXmark® liquid fiducials to enable radiotherapy tumor boosting in rectal cancer, a feasibility trial. ⁶²	Opbroek TJS...Berbee M	36407490	2023
4	Assessing the Association Between Endoscopic Tattooing and Lymph Node Yield in Rectal Cancer. ⁶²	Wlodarczyk J...Cologne KG	36115147	2023
5	MRI-based radiomics to predict neoadjuvant chemoradiotherapy outcomes in locally advanced rectal cancer: A multicenter study. ⁶²	Xiang Y...Wang W	36471751	2023
6	Standard versus longer interval of radical resection after neoadjuvant chemoradiotherapy in locally advanced rectal cancer: A 20-year single-center experience & propensity-score matching. ⁶²	Khamzina S...Park KJ	36169163	2023
7	The Effectiveness of a Self-management Program of Bowel Dysfunction in Patients With Mid and Low Rectal Cancer After Sphincter-Preserving Surgery: A Pilot Randomized Controlled Trial. ⁶²	Li C...Pang D	35089874	2023
8	Primary Colorectal Cancer. ⁶²	Dowli A...Fleshman J	36410915	2023
9	Assessing the role of robotic proctectomy in obese patients: a contemporary NSQIP analysis. ⁶²	Glencer AC...Sarin A	35147841	2022
10	Interischial Spine Distance Is a Simple Index of the Narrow Pelvis That Can Predict Difficulty During Laparoscopic Low Anterior Resection. ⁶²	Ichikawa N...Taketomi A	36223301	2022
11	Current trends in nonoperative management for rectal adenocarcinoma: An unequal playing field? ⁶²	Lee KC...Lopez NE	36056914	2022
12	Magnetic resonance imaging pelvimetry predicts the technical difficulty of rectal surgery. ⁶²	Ma Q...Shen Z	34961711	2022
13	Differences in Surgical Outcomes and Quality-of-Life Outcomes in Pelvic Exenteration Between Locally Advanced Versus Locally Recurrent Rectal Cancers. ⁶²	Huang Y...Solomon MJ	35913831	2022
14	Robotic versus laparoscopic total mesorectal excision for mid-low rectal cancer with difficult anatomical conditions. ⁶²	Pan J...Ren S	35168863	2022
15	Population pharmacokinetic analyses of regorafenib and capecitabine in patients with locally advanced rectal cancer (SAKK 41/16 RECAP). ⁶²	Schmulenson E...Jaehde U	35831229	2022
16	Could the STELLAR Study Change the Rectal Cancer Treatment Algorithm? ⁶²	Sutcuoglu O...Ozdemir N	35930767	2022
17	Risk of recurrence after local resection of T1 rectal cancer: a meta-analysis with meta-regression. ⁶²	Dekkers N...Boonstra JJ	35773606	2022
18	Correction to: The awareness of radiologists for the presence of lateral lymph nodes in patients with locally advanced rectal cancer: a single-centre, retrospective cohort study. ⁶²	Sluckin TC...Kusters M	35771250	2022
19	Current status of total neoadjuvant therapy for locally advanced rectal cancer. ⁶²	Feng W...Wang Y	34818447	2022
20	Radiology reporting in rectal cancer using MRI: adherence to national template for structured reporting. ⁶²	Alvfeldt G...Sellberg N	34866405	2022
21	Outcomes of laparoscopic versus robotic-assisted resection of T4 rectal cancer: propensity score-matched analysis of a national cancer database. ⁶²	Emile SH...Wexner SD	36471483	2022
22	A universal cell-free DNA approach for response prediction to preoperative chemoradiation in rectal cancer. ⁶²	Grinshpun A...Dor Y	36468189	2022
23	Role of IDO expression in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy. ⁶²	Takasu C...Shimada M	36471264	2022
24	"Their Whole Lives Are Going To Change": A Photo-Elicitation Study of Rectal Cancer Survivorship. ⁶²	Rivard SJ...Suwanabol PA	36382839	2022
25	Changing Patterns of Neoadjuvant Therapy for Locally Advanced Rectal Cancer: A Narrative Review. ⁶²	He W...Li X	36464124	2022
26	Staging and Restaging of Rectal Cancer with MRI: A Pictorial Review. ⁶²	Wetzel A...Purysko AS	36462804	2022
27	Extracellular volume fraction determined by equilibrium contrast-enhanced CT for the prediction of the pathological complete response to neoadjuvant chemoradiotherapy for locally advanced rectal cancer. ⁶²	Luo Y...Zhang J	36462046	2022
28	Determination of biomarkers associated with neoadjuvant treatment response focusing on colibactin-producing Escherichia coli in patients with mid or low rectal cancer: a prospective clinical study protocol (MICARE). ⁶²	Taoum C...Bonnet M	36460331	2022
29	Chemoradiotherapy in Locally Advanced Rectal Cancer: Surgeon Perspective. ⁶²	Yuksel BC	35930762	2022
30	Different neoadjuvant therapies for locally advanced rectal cancer: A systematic review and network meta-analysis. ⁶²	Petrelli F...Ghidini M	36252747	2022
31	The Impact of Postoperative Complications on Short- and Long-Term Health-Related Quality of Life After Total Mesorectal Excision for Rectal Cancer. ⁶²	van Kooten RT...Peeters KCMJ	36210321	2022
32	Tumour-stroma ratio to predict pathological response to neo-adjuvant treatment in rectal cancer. ⁶²	Strous MTA...de Bruine AP	36332556	2022
33	Life After Rectal Cancer Treatment: Time to Turn to the Experts. ⁶²	Morris AM	36382837	2022
34	The "Hands" teaching method applied to the anatomy of the inferior mesenteric artery related to rectal cancer surgery. ⁶²	Huang X	36450927	2022
35	Predicting tumor deposits in patients with rectal cancer: Using the models of multiple mathematical parameters derived from diffusion-weighted imaging. ⁶²	Hong Y...Li A	36347167	2022
36	Correcting rotational error in rectal cancer radiation therapy: Can planning target volume margins be safely reduced? ⁶²	Seah V...Lee M	35715996	2022
37	Alteration of Clinical Tumor Characteristics Is Associated with Pathological Regression in Locally Advanced Rectal Cancer After Neoadjuvant Chemoradiotherapy. ⁶²	Fu Z...Zheng M	36171472	2022
38	Outcomes of Locally Advanced Rectal Cancer Patients Treated with Total Neoadjuvant Treatment: A Meta-Anaysis of Randomized Controlled Trials. ⁶²	Gabbani M...Fiorica F	36210320	2022
39	Cost of postoperative complications of lower anterior resection for rectal cancer: a nationwide registry study of 15,187 patients. ⁶²	Kumamaru H...Miyata H	35608708	2022
40	A Deep Learning Model Based on MRI and Clinical Factors Facilitates Noninvasive Evaluation of KRAS Mutation in Rectal Cancer. ⁶²	Liu H...Wang D	35587946	2022
41	A Rectal Cancer Surgical Decision Aid Is Not Enough: A Qualitative Study. ⁶²	Goldwag JL...Ivatury SJ	36037408	2022
42	[Monotherapy with immune checkpoint blockade leads to clinical complete remission in patients with rectal cancer and microsatellite instability]. ⁶²	Diefenhardt M...Rodel C	35951038	2022
43	Unconsolidated Results of Consolidation Chemotherapy Following Short-Course Radiotherapy in Locally Advanced Rectal Cancer. ⁶²	Negri F...Aschele C	35930759	2022
44	Validation of pelvic magnetic resonance imaging as the method of choice to determine the distance to the anal margin in rectal cancer. ⁶²	Lorenzo Linan MA...Roig Vila JV	36064169	2022
45	Prognostic factors of pelvic MRI at the initial workflow in locally advanced rectal cancer: Focus on extra mural venous invasion and tumour deposits. ⁶²	Mayaud A...Magne N	35870953	2022
46	Usefulness of CT scan as part of an institutional protocol for proactive leakage management after low anterior resection for rectal cancer. ⁶²	Talboom K...Hompes R	36002771	2022
47	Total Neoadjuvant Therapy Is a Predictor for Complete Pathological Response in Patients Undergoing Surgery for Rectal Cancer. ⁶²	Horesh N...Wexner SD	36224480	2022
48	Comment on: Transanal Total Mesorectal Excision Versus Anterior Total Mesorectal Excision for Rectal Cancer: A Propensity Score-Matched, Population-Based Study in Catalonia, Spain. ⁶²	Ishiyama Y...Hirano Y	36102840	2022
49	Robotic vs. laparoscopic intersphincteric resection for low rectal cancer: a case matched study reporting a median of 7-year long-term oncological and functional outcomes. ⁶²	Aliyev V...Asoglu O	36198884	2022
50	The Role of Preoperative Imaging in the Detection of Lateral Lymph Node Metastases in Rectal Cancer: A Systematic Review and Diagnostic Test Meta-analysis. ⁶²	Rooney S...Joshi H	36102825	2022

Sources

Genes for Rectal Benign Neoplasm

Genes related to Rectal Benign Neoplasm (0 elite genes):

(show all 30)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	MSH2	MutS Homolog 2	Protein Coding	30.93	Likely pathogenic ⁵ DISEASES inferred ¹⁴
2	MIR145	MicroRNA 145	RNA Gene	8	DISEASES inferred ¹⁴ ¹⁴
3	MIR31	MicroRNA 31	RNA Gene	7.93	DISEASES inferred ¹⁴ ¹⁴
4	MIR143	MicroRNA 143	RNA Gene	7.51	DISEASES inferred ¹⁴ ¹⁴
5	MIR4753	MicroRNA 4753	RNA Gene	7.3	DISEASES inferred ¹⁴ ¹⁴
6	MIR17	MicroRNA 17	RNA Gene	7.21	DISEASES inferred ¹⁴ ¹⁴
7	CEACAM5	CEA Cell Adhesion Molecule 5	Protein Coding	7.13	DISEASES inferred ¹⁴
8	KRAS	KRAS Proto-Oncogene, GTPase	Protein Coding	7.03	DISEASES inferred ¹⁴
9	CAGE1	Cancer Antigen 1	Protein Coding	7.03	DISEASES inferred ¹⁴
10	HRAS	HRas Proto-Oncogene, GTPase	Protein Coding	6.86	DISEASES inferred ¹⁴
11	MIR1909	MicroRNA 1909	RNA Gene	6.82	DISEASES inferred ¹⁴ ¹⁴
12	MIR20A	MicroRNA 20a	RNA Gene	6.73	DISEASES inferred ¹⁴ ¹⁴
13	MIR99A	MicroRNA 99a	RNA Gene	6.58	DISEASES inferred ¹⁴ ¹⁴
14	MIRLET7A1	MicroRNA Let-7a-1	RNA Gene	6.53	DISEASES inferred ¹⁴ ¹⁴
15	DKKL1	Dickkopf Like Acrosomal Protein 1	Protein Coding	6.44	DISEASES inferred ¹⁴
16	RAB11B	RAB11B, Member RAS Oncogene Family	Protein Coding	6.44	DISEASES inferred ¹⁴
17	MLH1	MutL Homolog 1	Protein Coding	6.43	DISEASES inferred ¹⁴
18	TP53	Tumor Protein P53	Protein Coding	6.24	DISEASES inferred ¹⁴
19	LEPROTL1	Leptin Receptor Overlapping Transcript Like 1	Protein Coding	6.15	DISEASES inferred ¹⁴
20	MSH6	MutS Homolog 6	Protein Coding	6.07	DISEASES inferred ¹⁴
21	CDX2	Caudal Type Homeobox 2	Protein Coding	5.95	DISEASES inferred ¹⁴
22	PMS2	PMS1 Homolog 2, Mismatch Repair System Component	Protein Coding	5.84	DISEASES inferred ¹⁴
23	EGFR	Epidermal Growth Factor Receptor	Protein Coding	5.79	DISEASES inferred ¹⁴
24	RAB1A	RAB1A, Member RAS Oncogene Family	Protein Coding	5.72	DISEASES inferred ¹⁴
25	KRT7	Keratin 7	Protein Coding	5.72	DISEASES inferred ¹⁴
26	KRT20	Keratin 20	Protein Coding	5.67	DISEASES inferred ¹⁴
27	PIK3CA	Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha	Protein Coding	5.59	DISEASES inferred ¹⁴
28	CTNNB1	Catenin Beta 1	Protein Coding	5.54	DISEASES inferred ¹⁴
29	REEP5	Receptor Accessory Protein 5	Protein Coding	5.29	DISEASES inferred ¹⁴
30	TYMS	Thymidylate Synthetase	Protein Coding	5.24	DISEASES inferred ¹⁴

Sources

Variations for Rectal Benign Neoplasm

ClinVar genetic disease variations for Rectal Benign Neoplasm:

⁵

#	Gene	Name	Type	Significance	ClinVarId	dbSNP ID	Position
1	MSH2	NM_000251.3(MSH2):c.1313CTC[1] (p.Pro439del)	MICROSAT	Likely Pathogenic	90623	rs587779082	GRCh37: 2:47672723-47672725 GRCh38: 2:47445584-47445586

Sources

Expression for Rectal Benign Neoplasm

Search GEO for disease gene expression data for Rectal Benign Neoplasm.

Sources

Pathways for Rectal Benign Neoplasm

Pathways related to Rectal Benign Neoplasm according to GeneCards Suite gene sharing:

(show all 19)

#	Super pathways	Score	Top Affiliating Genes
1	TCR Signaling (Qiagen) ⁶⁴ Show member pathways Fc-EpsilonRI Pathway ⁶⁴ ITK and TCR Signaling ⁶⁴ PDGF Pathway ⁶⁴ PKC-Theta Pathway ⁶⁴	12.71	HRAS KRAS MLH1 MSH2 MSH6 TP53
2	Endometrial cancer ⁷⁴ Show member pathways Chromosomal and microsatellite instability in colorectal cancer ⁷⁴ Melanoma ⁷⁴ Non-small cell lung cancer ⁷⁴ Pancreatic adenocarcinoma pathway ⁷⁴ Signal transduction PTEN pathway ²²	12.35	TP53 MSH6 MSH2 MLH1 KRAS HRAS
3	DNA Damage ³	12.34	TP53 MSH6 MSH2 MLH1
4	Integrated breast cancer pathway ⁷⁴	11.96	KRAS MSH2 MSH6 TP53
5	DNA damage response (only ATM dependent) ⁷⁴	11.76	TP53 KRAS HRAS
6	p53 transcriptional gene network ⁷⁴	11.71	MSH2 MLH1 MIR145
7	BRCA1 Pathway ⁶⁴ Show member pathways Fanconi's Anaemia Pathway ⁶⁴	11.63	TP53 MSH6 MSH2
8	DNA IR-damage and cellular response via ATR ⁷⁴	11.61	TP53 MSH2 MLH1
9	mTOR Pathway ⁷⁰ Show member pathways TGF-beta Pathway ⁷⁰	11.58	TP53 KRAS HRAS
10	Colorectal Cancer Metastasis ⁶⁴	11.57	TP53 MSH6 MSH2 MLH1 KRAS
11	Head and neck squamous cell carcinoma ⁷⁴	11.53	TP53 KRAS HRAS
12	Cell differentiation - expanded index ⁷⁴ Show member pathways Cell differentiation - index ⁷⁴	11.35	MIR20A MIR17 MIR145 MIR143
13	Doxorubicin Pathway, Pharmacokinetics ⁶⁰ Show member pathways Doxorubicin Pathway (Cancer Cell), Pharmacodynamics ⁶⁰	11.21	TP53 MSH2 MLH1
14	Bladder cancer ⁷⁴	11.18	TP53 KRAS HRAS
15	Transcription_Transcription factor Tubby signaling pathways ²²	11.17	TP53 KRAS HRAS
16	Integrated cancer pathway ⁷⁴	11.12	TP53 MSH6 MSH2
17	Platinum Pathway, Pharmacokinetics/Pharmacodynamics ⁶⁰	10.96	MSH6 MSH2 MLH1
18	miRNAs involved in DNA damage response ⁷⁴	10.93	TP53 MIRLET7A1 MIR20A MIR17 MIR145 MIR143
19	TNF-alpha signaling pathway ⁷⁴ Show member pathways RAS GTPase cycle mutants ⁶⁶ Signaling by RAS GAP mutants ⁶⁶ Signaling by RAS GTPase mutants ⁶⁶	10.63	KRAS HRAS

Sources

GO Terms for Rectal Benign Neoplasm

Cellular components related to Rectal Benign Neoplasm according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	extracellular vesicle	GO:1903561	9.46	MIRLET7A1 MIR99A MIR20A MIR17
2	RISC complex	GO:0016442	9.44	MIRLET7A1 MIR99A MIR31 MIR20A MIR17 MIR145
3	mismatch repair complex	GO:0032300	9.43	MSH2 MLH1
4	MutSalpha complex	GO:0032301	9.26	MSH6 MSH2

Biological processes related to Rectal Benign Neoplasm according to GeneCards Suite gene sharing:

(show all 21)

#	Name	GO ID	Score	Top Affiliating Genes
1	miRNA-mediated gene silencing	GO:0035195	10.31	MIR143 MIR145 MIR17 MIR20A MIR31 MIR99A
2	intrinsic apoptotic signaling pathway	GO:0097193	10	TP53 MSH6 HRAS
3	intrinsic apoptotic signaling pathway in response to DNA damage	GO:0008630	9.99	MSH6 MSH2 MLH1
4	mismatch repair	GO:0006298	9.99	MSH6 MSH2 MLH1
5	determination of adult lifespan	GO:0008340	9.93	TP53 MSH6 MSH2
6	isotype switching	GO:0045190	9.91	MSH6 MSH2 MLH1
7	positive regulation of helicase activity	GO:0051096	9.88	MSH6 MSH2
8	positive regulation of isotype switching to IgA isotypes	GO:0048298	9.84	MLH1 MSH2
9	somatic hypermutation of immunoglobulin genes	GO:0016446	9.73	MSH6 MSH2 MLH1
10	maintenance of DNA repeat elements	GO:0043570	9.72	MSH2 MSH6
11	angiotensin-activated signaling pathway	GO:0038166	9.6	MIR145 MIR143
12	positive regulation of cardiac muscle hypertrophy in response to stress	GO:1903244	9.58	MIR20A MIR17
13	somatic recombination of immunoglobulin genes involved in immune response	GO:0002204	9.58	MSH2 MLH1
14	negative regulation of interleukin-6-mediated signaling pathway	GO:0070104	9.57	MIRLET7A1 MIR99A
15	aorta smooth muscle tissue morphogenesis	GO:0060414	9.56	MIR145 MIR143
16	somatic recombination of immunoglobulin gene segments	GO:0016447	9.55	MSH6 MSH2 MLH1
17	negative regulation of amyloid precursor protein biosynthetic process	GO:0042985	9.5	MIR31 MIR20A MIR17
18	regulation of phenotypic switching	GO:1900239	9.48	MIR145 MIR143
19	establishment or maintenance of cell type involved in phenotypic switching	GO:0044663	9.37	MIR143 MIR145
20	miRNA-mediated gene silencing by inhibition of translation	GO:0035278	9.35	MIRLET7A1 MIR31 MIR20A MIR17 MIR145
21	positive regulation of pulmonary blood vessel remodeling	GO:1905111	8.8	MIR20A MIR17 MIR143

Molecular functions related to Rectal Benign Neoplasm according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	G protein activity	GO:0003925	9.91	RAB11B KRAS HRAS
2	ATP-dependent DNA damage sensor activity	GO:0140664	9.8	MLH1 MSH2 MSH6
3	MutLalpha complex binding	GO:0032405	9.78	MSH6 MSH2
4	oxidized purine DNA binding	GO:0032357	9.76	MSH6 MSH2
5	single guanine insertion binding	GO:0032142	9.71	MSH6 MSH2
6	mRNA 3'-UTR binding	GO:0003730	9.7	TP53 MIR31 MIR20A MIR17 MIR145 MIR143
7	single thymine insertion binding	GO:0032143	9.67	MSH6 MSH2
8	mismatched DNA binding	GO:0030983	9.65	MSH6 MSH2 MLH1
9	guanine/thymine mispair binding	GO:0032137	9.43	MSH6 MSH2 MLH1
10	mRNA base-pairing translational repressor activity	GO:1903231	9.17	MIRLET7A1 MIR99A MIR31 MIR20A MIR17 MIR145